Anadys Pharmaceuticals (ANDS)
ANDS - NASDAQ - 3/16/2010 11:36 AM
2.21
Change 0.04
% Change 1.84%
| Market Cap | Revenue Growth | Profit Margin | Cash |
|---|---|---|---|
| $80.96M | N/A | N/A | $20.48M |
| 3570 / 4588 | N/A / 4575 | N/A / 4574 | 2921 / 4125 |
For the December 2009 quarter, Anadys Pharmaceuticals spent an unknown percentage of gross profits on R&D and an unknown percentage on SGA expenses. Revenues rose an unknown amount year-over-year to $0. The company is trading at an unknown amount times earnings(PE) and an unknown amount times revenue(PSR). At the end of December 2009, Anadys Pharmaceuticals had $20.48M in cash on hand and $0 in long-term debt. On 02/24/2010, Anadys Pharmaceuticals reported net loss of $4.26M, with diluted earnings per share of $-0.11.